Literature DB >> 8522326

Selection against blood cells deficient in hypoxanthine phosphoribosyltransferase (HPRT) in Lesch-Nyhan heterozygotes occurs at the level of multipotent stem cells.

M Hakoda1, Y Hirai, M Akiyama, H Yamanaka, C Terai, N Kamatani, S Kashiwazaki.   

Abstract

Lesch-Nyhan syndrome is caused by a severe genetic deficiency of hypoxanthine phosphoribosyltransferase (HPRT) and is characterized by central nervous system disorders, gout, and in some cases, macrocytic anemia. Women heterozygous for HPRT deficiency are healthy but their somatic cells are mosaic for enzyme deficiency owing to random inactivation of the X chromosome. Frequencies of red blood cells and T cells deficient in HPRT are significantly lower than the expected 50% in heterozygotes, suggesting that HPRT-negative blood cells are selected against in heterozygotes. To determine at which stage of hematopoiesis such selection occurs, we determined the frequencies of HPRT-negative T, B and erythroid precursor cells in three heterozygotes. Since the cloning efficiencies of T and B cells and colony forming efficiency of burst-forming unit erythroid (BFU-E) for sample from Lesch-Nyhan patients were similar to those of normal cells, HPRT deficiency does not seem to render the differentiated cells less efficient for proliferation. However, the frequencies of HPRT-negative T and B cells, and BFU-E were all less than 10% in each of the three heterozygotes. Although the frequencies of HPRT-negative cells showed tenfold variations between the heterozygotes, each heterozygote had similar frequencies of HPRT-negative cells in the three cell types. These results suggest that HPRT is important at early stages of hematopoiesis, but less so after the cells have differentiated into T cells, B cells and erythroid precursor cells.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8522326     DOI: 10.1007/bf00210298

Source DB:  PubMed          Journal:  Hum Genet        ISSN: 0340-6717            Impact factor:   4.132


  35 in total

1.  Two populations of heterozygote erythrocytes in moderate hypoxanthine guanine phosphoribosyltransferase deficiency.

Authors:  L A Johnson; R B Gordon; B T Emmerson
Journal:  Nature       Date:  1976-11-11       Impact factor: 49.962

2.  Molecular analyses of in vivo hprt mutant T cells from atomic bomb survivors.

Authors:  M Hakoda; Y Hirai; S Kyoizumi; M Akiyama
Journal:  Environ Mol Mutagen       Date:  1989       Impact factor: 3.216

3.  Detection of somatic mutants in man: HPRT mutations in lymphocytes and hemoglobin mutations in erythrocytes.

Authors:  A D Tates; L F Bernini; A T Natarajan; J S Ploem; N P Verwoerd; J Cole; M H Green; C F Arlett; P N Norris
Journal:  Mutat Res       Date:  1989-07       Impact factor: 2.433

4.  Measurement of in vivo HGPRT-deficient mutant cell frequency using a modified method for cloning human peripheral blood T-lymphocytes.

Authors:  M Hakoda; M Akiyama; S Kyoizumi; K Kobuke; A A Awa; M Yamakido
Journal:  Mutat Res       Date:  1988-01       Impact factor: 2.433

5.  Lesch-Nyhan syndrome: absence of the mutant enzyme in erythrocytes of a heterozygote for both normal and mutant hypoxanthine-guanine phosphoribosyl transferase.

Authors:  J A McDonald; W N Kelley
Journal:  Biochem Genet       Date:  1972-02       Impact factor: 1.890

6.  Megaloblastic anaemia in the Lesch-Nyhan syndrome.

Authors:  S P van der Zee; E D Schretlen; L A Monnens
Journal:  Lancet       Date:  1968-06-29       Impact factor: 79.321

7.  Molecular characterization of 15 rearrangements among 90 human in vivo somatic mutants shows that deletions predominate.

Authors:  W E Bradley; J L Gareau; A M Seifert; K Messing
Journal:  Mol Cell Biol       Date:  1987-02       Impact factor: 4.272

8.  Cloning of in vivo-derived thioguanine-resistant human B cells.

Authors:  M Hakoda; Y Hirai; Y Kusunoki; M Akiyama
Journal:  Mutat Res       Date:  1989-01       Impact factor: 2.433

9.  Observations on the growth in vitro of myeloid progenitor cells and fibroblasts from hemizygotes and heterozygotes for "complete" and "partial" hypoxanthine-guanine phosphoribosyltransferase (HGPRT) deficiency, and their relevance to the pathogenesis of brain damage in the Lesch-Nyhan syndrome.

Authors:  R O McKeran; A Howell; T M Andrews; R W Watts; C F Arlett
Journal:  J Neurol Sci       Date:  1974-06       Impact factor: 3.181

10.  Detection of the carrier state for an X-linked disorder, the Lesch-Nyhan syndrome, by the use of lymphocyte cloning.

Authors:  J L Dempsey; A A Morley; R S Seshadri; B T Emmerson; R Gordon; C I Bhagat
Journal:  Hum Genet       Date:  1983       Impact factor: 4.132

View more
  5 in total

1.  Frequency and cytokine profile of HPRT mutant T cells in HIV-infected and healthy donors: implications for T cell proliferation in HIV disease.

Authors:  C Paganin; D S Monos; J D Marshall; I Frank; G Trinchieri
Journal:  J Clin Invest       Date:  1997-02-15       Impact factor: 14.808

2.  Skewed X inactivation in Lesch-Nyhan disease carrier females.

Authors:  Rosa J Torres; Juan G Puig
Journal:  J Hum Genet       Date:  2017-09-14       Impact factor: 3.172

3.  Perfecting a high hypoxanthine phosphoribosyltransferase activity-uricase KO mice to test the effects of purine- and non-purine-type xanthine dehydrogenase (XDH) inhibitors.

Authors:  Takuji Hosoya; Shunya Uchida; Shigeru Shibata; Naoko H Tomioka; Makoto Hosoyamada
Journal:  Br J Pharmacol       Date:  2020-02-18       Impact factor: 8.739

Review 4.  Dosage Compensation in Females with X-Linked Metabolic Disorders.

Authors:  Patrycja Juchniewicz; Ewa Piotrowska; Anna Kloska; Magdalena Podlacha; Jagoda Mantej; Grzegorz Węgrzyn; Stefan Tukaj; Joanna Jakóbkiewicz-Banecka
Journal:  Int J Mol Sci       Date:  2021-04-26       Impact factor: 5.923

Review 5.  Hypoxanthine-guanine phosophoribosyltransferase (HPRT) deficiency: Lesch-Nyhan syndrome.

Authors:  Rosa J Torres; Juan G Puig
Journal:  Orphanet J Rare Dis       Date:  2007-12-08       Impact factor: 4.123

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.